Q3 2014 13F Holders as of 30 Sep 2014
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
104,661,494
-
Number of holders
-
80
-
Total 13F shares, excl. options
-
15,656,921
-
Shares change
-
-833,601
-
Total reported value, excl. options
-
$302,653,761
-
Value change
-
-$45,140,381
-
Number of buys
-
48
-
Number of sells
-
-46
-
Price
-
$19.33
Significant Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q3 2014
107 filings reported holding RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q3 2014.
Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) has 80 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 15,656,921 shares
of 104,661,494 outstanding shares and own 14.96% of the company stock.
Largest 10 shareholders include Essex Woodlands Health Ventures, Inc. (4,592,047 shares), FRANKLIN RESOURCES INC (1,386,899 shares), FMR LLC (1,029,800 shares), JPMORGAN CHASE & CO (790,817 shares), Arrowpoint Asset Management, LLC (702,550 shares), Polar Capital LLP (689,780 shares), COLUMBIA WANGER ASSET MANAGEMENT LLC (562,000 shares), ALLIANCEBERNSTEIN L.P. (515,614 shares), GOLDMAN SACHS GROUP INC (425,445 shares), and RS INVESTMENT MANAGEMENT CO LLC (421,566 shares).
This table shows the top 80 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.